UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): | July 18, 2011 |
StemCells, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
Delaware | 000-19871 | 94-3078125 |
_____________________ (State or other jurisdiction |
_____________ (Commission |
______________ (I.R.S. Employer |
of incorporation) | File Number) | Identification No.) |
7707 Gateway Blvd, Suite 140, Newark, California | 94560 | |
_________________________________ (Address of principal executive offices) |
___________ (Zip Code) |
Registrants telephone number, including area code: | 650.456.4000 |
3155 Porter Dr, Palo Alto, CA, 94304
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On July 18, 2011, StemCells, Inc. (the "Company") announced the relocation of its corporate headquarters and U.S.-based research and development operations to 7707 Gateway Blvd, Newark, CA 94560.
The Company's press release announcing its corporate relocation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incororated hereby by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1 Press Release of StemCells, Inc., dated July 18, 2011
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
StemCells, Inc. | ||||
July 18, 2011 | By: |
/s/ Kenneth Stratton
|
||
|
||||
Name: Kenneth Stratton | ||||
Title: General Counsel |
Exhibit Index
Exhibit No. | Description | |
|
|
|
99.1
|
Press Release of StemCells, Inc., dated July 18, 2011 |
NEWS RELEASE
FOR IMMEDIATE RELEASE
CONTACT: | Rodney Young Chief Financial Officer (510) 456-4128 |
STEMCELLS, INC. RELOCATES CORPORATE HEADQUARTERS
AND U.S. RESEARCH LABS
Newark, Calif., July 18, 2011 StemCells, Inc. (Nasdaq:STEM) announced today that it has relocated its corporate headquarters and U.S.-based research and development operations to 7707 Gateway Blvd, Newark, CA 94560, USA. The new facilities comprise newly constructed, custom designed laboratory and office space, and will house the majority of the Companys U.S. workforce. The Companys new main telephone number is (510) 456-4000.
This is a win win situation for employees and shareholders alike, said Martin McGlynn, President and CEO of StemCells. Not only are we providing our scientists with modern, state of the art, R&D facilities designed to foster their ground breaking work, but by moving to the Pacific Research Center in Newark, we are significantly reducing the Companys annual facility lease and operating expenses.
StemCells other facilities in Cambridge, U.K., where the Company researches, develops and manufactures its SC Proven® line of media and reagent products, and in Mountain View, California, are not affected by this move.
About StemCells, Inc.
StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Companys lead therapeutic product candidate, HuCNS-SC® cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. Clinical trials are currently underway in spinal cord injury and in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children. In addition, the Company plans to file an IND by year-end 2011 to initiate a clinical trial of HuCNS-SC cells in age-related macular degeneration, and is also pursuing preclinical studies of its HuCNS-SC cells in Alzheimers disease and stroke. StemCells also markets stem cell research products, including media and reagents, under the SC Proven® brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery and drug development. Further information about StemCells is available at http://www.stemcellsinc.com.
Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the U.S. securities laws, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding the future business operations of StemCells, Inc. (the Company), including the anticipated reduction in operating expenses from the Companys relocation to Newark, California. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect managements current views and are based on certain assumptions that may or may not ultimately prove valid. The Companys actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including those described under the heading Risk Factors in the Companys Annual Report on Form 10-K for the year ended December 31, 2010 and in its subsequent reports on Form 10-Q and Form 8-K.
# # # #